VANCOUVER, Jan. 10, 2013 /PRNewswire/ - Anavex Life Sciences Corp. ("Anavex")
(OTCQB: AVXL) announces the appointment of Athanasios (Tom) Skarpelos
as a Director of the company effective January 9, 2013.
"Tom has been actively involved in Anavex since the very beginning,"
said Sean Lowry, former Director of Anavex. "His passion for Anavex and
its assets, and his relationships with people and organizations close
to the company have characterized the company's development since its
foundation. This is a significant commitment on Tom's part, and we
wish him well in developing life-saving treatments for serious
"I am excited to be leading Anavex as we try to alleviate the suffering
of millions of people afflicted by debilitating disease," said Mr.
Skarpelos. "We intend to evaluate ANAVEX 2-73's progress in the
treatment of Alzheimer's disease, and to strategically deploy our
resources to further our business plans. As well, I look forward to
expanding Anavex' leadership team."
Mr. Skarpelos is a self-employed investor with 17 years of experience
working with private and public companies. For the past 10 years, he
has been focused on biotechnology companies involved in drug discovery
and drug development projects. Mr. Skarpelos was engaged as a
consultant to Anavex Life Sciences for one year effective August 2,
2010. His experience has led to relationships with researchers at
academic institutes in Europe and North America. Mr. Skarpelos is a
founder of Anavex Life Sciences, and is its largest shareholder.
Anavex announces that Robert Chisholm has terminated his agreement, and
resigned as President, Secretary, Treasurer, Chief Financial Officer,
and as a Director of Anavex effective January 9, 2013. Effective the
same date, Sean Lowry resigned as a Director of Anavex.
About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (www.anavex.com) is a pharmaceutical company engaged in the development of novel drug
candidates. ANAVEX 2-73, a drug candidate developed to treat
Alzheimer's disease through disease modification, is in human clinical
trials. Sponsored studies indicate that ANAVEX 2-73 demonstrates
anti-amnesic and neuroprotective properties, and that it is well
tolerated in doses up to 55mg. Anavex is a publicly traded corporation
quoted as AVXL.
Forward-Looking Statements Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Forward-looking statements in this
press release include that we intend to evaluate ANAVEX 2-73's
progress, that we intend to deploy resources in furtherance of business
plans, that we will expand our leadership team, that ANAVEX 2-73 is in
human clinical trials, and that data from a prior trial indicates that
the compound is well tolerated. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in drug
discovery and development, which include, without limitation, the
potential failure of development candidates to advance through
preclinical studies or demonstrate safety and efficacy in clinical
testing and the ability to pass clinical trials so as to move on to the
next phase, our ability to finance development or satisfy the rigorous
regulatory requirements for new drugs, our ability to attract and
retain quality personnel, and that despite positive results, our
competitors may offer better or cheaper alternatives. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary statement
and Anavex Life Sciences Corp. undertakes no obligation to revise or
update this press release to reflect events or circumstances after the
Anavex Life Sciences Corp. Research & Business Development Email: firstname.lastname@example.org
Shareholder & Media Relations Toll-free: 1-866-505-2895 Outside North America: +1 (416) 489-0092 Email: email@example.com www.anavex.com
SOURCE Anavex Life Sciences Corp.